NeuroBo Pharmaceuticals Inc (NAS:NRBO)
$ 4.13 0.155 (3.9%) Market Cap: 20.26 Mil Enterprise Value: 4.46 Mil PE Ratio: 0 PB Ratio: 2.01 GF Score: 38/100

NeuroBo Pharmaceuticals, Inc., Gemphire Therapeutics Inc. - M&A Call Transcript

Jul 25, 2019 / 12:30PM GMT
Release Date Price: $5550 (+28.47%)
Operator

Good morning, ladies and gentlemen. Thank you for joining us today for the Gemphire-NeuroBo Pharmaceuticals joint conference call to discuss the proposed merger of Gemphire with NeuroBo Pharmaceuticals, as we announced in the press release yesterday afternoon.

I would now like to turn the call over to Steve Gullans, Chief Executive Officer of Gemphire. Please go ahead, sir.

Steven R. Gullans
Gemphire Therapeutics Inc. - CEO, President, Director, Principal Financial Officer & Principal Accounting Officer

Thank you, Kevin, and thank you all for joining us today. Please note, there are slides accompanying today's call. To access these, go to the Investors & Media section of the Gemphire or NeuroBo corporate websites. Look under Events and Presentations, and you'll find them. Joining me today is John Brooks, Chief Executive Officer of NeuroBo.

But before we begin, we advise that certain remarks that are made during this call will include remarks about future expectations, plans and prospects for NeuroBo and Gemphire, which constitutes

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot